PHA121, Oral Therapy for HAE Attacks, Safe at All Doses in Phase 1 Trial

PHA121, Oral Therapy for HAE Attacks, Safe at All Doses in Phase 1 Trial

284583

PHA121, Oral Therapy for HAE Attacks, Safe at All Doses in Phase 1 Trial

PHA121, an investigational oral therapy for hereditary angioedema attacks, was well tolerated across multiple doses in a group of healthy volunteers in a Phase 1 trial. Study data also indicates that PHA121 reached therapeutic levels in the first day of a 10-day treatment period, and stable levels within the first three days. “We are encouraged by these results to continue development of PHA121 as an oral treatment for hereditary angioedema,” Berndt Modig, CEO and co-founder…

You must be logged in to read/download the full post.